Enzychem Lifesciences Corporation (183490.KQ)

KRW 1080.0

(0.19%)

Net Income Summary of Enzychem Lifesciences Corporation

Enzychem Lifesciences Corporation's latest annual net income in 2023 was -9.32 Billion KRW , up 62.83% from previous year.
Enzychem Lifesciences Corporation's latest quarterly net income in 2024 Q2 was -3.36 Billion KRW , down -208.64% from previous quarter.
Enzychem Lifesciences Corporation reported an annual net income of -25.09 Billion KRW in 2022, up 9.95% from previous year.
Enzychem Lifesciences Corporation reported an annual net income of -27.86 Billion KRW in 2021, down -59.16% from previous year.
Enzychem Lifesciences Corporation reported a quarterly net income of -3.36 Billion KRW for 2024 Q2, down -208.64% from previous quarter.
Enzychem Lifesciences Corporation reported a quarterly net income of -1.83 Billion KRW for 2023 Q4, up 30.45% from previous quarter.

Annual Net Income Chart of Enzychem Lifesciences Corporation (2023 - 2016)

Historical Annual Net Income of Enzychem Lifesciences Corporation (2023 - 2016)

Year	Net Income	Net Income Growth
2023	-9.32 Billion KRW	62.83%
2022	-25.09 Billion KRW	9.95%
2021	-27.86 Billion KRW	-59.16%
2020	-17.5 Billion KRW	-3.72%
2019	-16.87 Billion KRW	-17.05%
2018	-14.42 Billion KRW	-154.49%
2017	-5.66 Billion KRW	10.51%
2016	-6.33 Billion KRW	0.0%

Year	Net Income	Net Income Growth
2024 Q1	-1.08 Billion KRW	40.59%
2024 Q2	-3.36 Billion KRW	-208.64%
2023 Q4	-1.83 Billion KRW	30.45%
2023 Q1	-2.4 Billion KRW	72.23%
2023 Q2	-2.45 Billion KRW	-2.05%
2023 FY	-9.32 Billion KRW	62.83%
2023 Q3	-2.63 Billion KRW	-7.34%
2022 Q2	-5.1 Billion KRW	20.32%
2022 FY	-25.09 Billion KRW	9.95%
2022 Q4	-8.65 Billion KRW	-75.89%
2022 Q3	-4.92 Billion KRW	3.56%
2022 Q1	-6.4 Billion KRW	12.42%
2021 Q1	-6.8 Billion KRW	-55.63%
2021 FY	-27.86 Billion KRW	-59.16%
2021 Q4	-7.31 Billion KRW	-4.73%
2021 Q3	-6.98 Billion KRW	-8.35%
2021 Q2	-6.44 Billion KRW	5.33%
2020 Q4	-4.37 Billion KRW	16.81%
2020 Q3	-5.25 Billion KRW	-45.41%
2020 Q1	-4.19 Billion KRW	24.58%
2020 Q2	-3.61 Billion KRW	13.71%
2020 FY	-17.5 Billion KRW	-3.72%
2019 Q3	-2.19 Billion KRW	60.0%
2019 Q1	-3.2 Billion KRW	-3.65%
2019 FY	-16.87 Billion KRW	-17.05%
2019 Q4	-5.55 Billion KRW	-153.21%
2019 Q2	-5.48 Billion KRW	-71.26%
2018 FY	-14.42 Billion KRW	-154.49%
2018 Q2	-2.71 Billion KRW	57.16%
2018 Q4	-3.09 Billion KRW	-36.36%
2018 Q3	-2.26 Billion KRW	16.58%
2018 Q1	-6.34 Billion KRW	-872.81%
2017 Q2	-1.49 Billion KRW	0.0%
2017 FY	-5.66 Billion KRW	10.51%
2017 Q3	-1.66 Billion KRW	-10.71%
2017 Q4	-652.13 Million KRW	60.72%
2016 FY	-6.33 Billion KRW	0.0%

Peer Net Income Comparison of Enzychem Lifesciences Corporation

Name	Net Income	Net Income Difference
HLB Pharmaceutical Co., Ltd	-19.42 Billion KRW	51.994%
CMG Pharmaceutical Co., Ltd.	6.45 Billion KRW	244.476%
Celltrion Pharm, Inc.	21.26 Billion KRW	143.858%
Huons Global Co., Ltd.	38.38 Billion KRW	124.298%
DongKook Pharmaceutical Co., Ltd.	47.17 Billion KRW	119.77%
Humedix Co., Ltd.	24.82 Billion KRW	137.575%
Boditech Med Inc.	25.94 Billion KRW	135.945%
EuBiologics Co., Ltd.	-13.87 Billion KRW	32.802%
FutureChem Co.,Ltd	-6.7 Billion KRW	-39.015%
Huons Co., Ltd.	50.47 Billion KRW	118.478%
BNC Korea Co., Ltd.	25.68 Billion KRW	136.309%
AptaBio Therapeutics Inc.	-12.06 Billion KRW	22.677%